New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
07:17 EDTHZNPHorizon Pharma acquisition to be significantly accretive, says Stifel
After Horizon Pharma announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon's deal activity is favorable overall as it increases product diversity and leverages the company's promotional activities. Stifel keeps an $18 price target and Buy rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
16:12 EDTHZNPHorizon Pharma reports positive effect of RAYOS in reducing joint stiffness
Subscribe for More Information
November 14, 2014
08:06 EDTHZNPHorizon Pharma 11.66M share Secondary priced at $12.05
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use